- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 436786, 10 pages
Ethanolic Extract of Vitis thunbergii Exhibits Lipid Lowering Properties via Modulation of the AMPK-ACC Pathway in Hypercholesterolemic Rabbits
1School of Pharmacy, China Medical University, Taichung 40402, Taiwan
2Research and Development Department, Medigreen Biotechnology Corporation, Taipei 22046, Taiwan
Received 13 October 2011; Revised 19 January 2012; Accepted 20 January 2012
Academic Editor: Myeong Soo Lee
Copyright © 2012 Chun-Hsu Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. N. Baer and R. L. Wortmann, “Myotoxicity associated with lipid-lowering drugs,” Current Opinion in Rheumatology, vol. 19, no. 1, pp. 67–73, 2007.
- J. Adams, Z. P. Chen, B. J. W. Van Denderen et al., “Intrasteric control of AMPK via the γ1 subunit AMP allosteric regulatory site,” Protein Science, vol. 13, no. 1, pp. 155–165, 2004.
- J. M. Lee, W. Y. Seo, K. H. Song et al., “AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB·CRTC2 complex by orphan nuclear receptor small heterodimer partner,” Journal of Biological Chemistry, vol. 285, no. 42, pp. 32182–32191, 2010.
- D. G. Hardie, “The AMP-activated protein kinase pathway—new players upstream and downstream,” Journal of Cell Science, vol. 117, no. 23, pp. 5479–5487, 2004.
- E. O. Ojuka, “Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle,” Proceedings of the Nutrition Society, vol. 63, no. 2, pp. 275–278, 2004.
- D. G. Hardie and D. A. Pan, “Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase,” Biochemical Society Transactions, vol. 30, no. 6, pp. 1064–1070, 2002.
- P. R. Clarke and D. G. Hardie, “Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver,” EMBO Journal, vol. 9, no. 8, pp. 2439–2446, 1990.
- Z. An, H. Wang, P. Song, M. Zhang, X. Geng, and M. H. Zou, “Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress,” Journal of Biological Chemistry, vol. 282, no. 37, pp. 26793–26801, 2007.
- Y. L. Huang, S. H. Loke, C. C. Hsu, and W. F. Chiou, “(+)-Vitisin A inhibits influenza A virus-induced RANTES production in A549 alveolar epithelial cells through interference with Akt and STAT1 phosphorylation,” Planta Medica, vol. 74, no. 2, pp. 156–162, 2008.
- K. T. Ku, Y. L. Huang, Y. J. Huang, and W. F. Chiou, “Miyabenol A inhibits LPS-induced NO production via IKK/IκB inactivation in RAW 264.7 macrophages: possible involvement of the p38 and PI3K pathways,” Journal of Agricultural and Food Chemistry, vol. 56, no. 19, pp. 8911–8918, 2008.
- Y. L. Huang, W. J. Tsai, C. C. Shen, and C. C. Chen, “Resveratrol derivatives from the roots of Vitis thunbergii,” Journal of Natural Products, vol. 68, no. 2, pp. 217–220, 2005.
- L. L. Lin, C. Y. Lien, Y. C. Cheng, and K. L. Ku, “An effective sample preparation approach for screening the anticancer compound piceatannol using HPLC coupled with UV and fluorescence detection,” Journal of Chromatography B, vol. 853, no. 1-2, pp. 175–182, 2007.
- S. C. Peng, C. Y. Cheng, F. Sheu, and C. H. Su, “The antimicrobial activity of heyneanol A extracted from the root of taiwanese wild grape,” Journal of Applied Microbiology, vol. 105, no. 2, pp. 485–491, 2008.
- I.-M. Chung, M.-A. Yeo, S.-J. Kim, and H.-I. Moon, “Neuroprotective effects of resveratrol derivatives from the roots of Vitis thunbergii var. sinuate against glutamate-induced neurotoxicity in primary cultured rat cortical cells,” Human and Experimental Toxicology, vol. 30, no. 9, pp. 1404–1408, 2011.
- C. K. Wang, L. G. Chen, C. L. Wen et al., “Neuroprotective activity of vitis thunbergii var. taiwaniana extracts in vitro and in vivo,” Journal of Medicinal Food, vol. 13, no. 1, pp. 170–178, 2010.
- W. F. Chiou, C. C. Shen, C. C. Chen, C. H. Lin, and Y. L. Huang, “Oligostilbenes from the roots of Vitis thunbergii,” Planta Medica, vol. 75, no. 8, pp. 856–859, 2009.
- S. C. Yang, Studies on the Chemical Constituents of the Stems of Vitis thunbergii Sieb. et Zucc, M.S. thesis, China Medical University, Taichung, Taiwan, 2005.
- J. M. Wu, Z. R. Wang, T. C. Hsieh, J. L. Bruder, J. G. Zou, and Y. Z. Huang, “Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review),” International journal of molecular medicine, vol. 8, no. 1, pp. 3–17, 2001.
- H. Berrougui, G. Grenier, S. Loued, G. Drouin, and A. Khalil, “A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux,” Atherosclerosis, vol. 207, no. 2, pp. 420–427, 2009.
- V. R. Ramprasath and P. J. H. Jones, “Anti-atherogenic effects of resveratrol,” European Journal of Clinical Nutrition, vol. 64, no. 7, pp. 660–668, 2010.
- S. Das, G. A. Cordis, N. Maulik, and D. K. Das, “Pharmacological preconditioning with resveratrol: Role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation,” American Journal of Physiology, vol. 288, no. 1, pp. H328–H335, 2005.
- S. Das and D. K. Das, “Resveratrol: a therapeutic promise for cardiovascular diseases,” Recent Patents on Cardiovascular Drug Discovery, vol. 2, no. 2, pp. 133–138, 2007.
- R. I. Kirk, J. A. Deitch, J. M. Wu, and K. M. Lerea, “Resveratrol decreases early signaling events in washed platelets but has little effect on platelet aggregation in whole blood,” Blood Cells, Molecules, and Diseases, vol. 26, no. 2, pp. 144–150, 2000.
- U. R. Pendurthi, J. T. Williams, and L. V. M. Rao, “Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: a possible mechanism for the cardiovascular benefits associated with moderate consumption of wine,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 2, pp. 419–426, 1999.
- R. Zini, C. Morin, A. Bertelli, A. A. E. Bertelli, and J. P. Tillement, “Effects of resveratrol on the rat brain respiratory chain,” Drugs under Experimental and Clinical Research, vol. 25, no. 2-3, pp. 87–97, 1999.
- M. Jang and J. M. Pezzuto, “Cancer chemopreventive activity of resveratrol,” Drugs under Experimental and Clinical Research, vol. 25, no. 2-3, pp. 65–77, 1999.
- P. S. Ray, G. Maulik, G. A. Cordis, A. A. E. Bertelli, A. Bertelli, and D. K. Das, “The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury,” Free Radical Biology and Medicine, vol. 27, no. 1-2, pp. 160–169, 1999.
- S. K. Manna, A. Mukhopadhyay, and B. B. Aggarwal, “Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation,” Journal of Immunology, vol. 164, no. 12, pp. 6509–6519, 2000.
- Y. Kimura, H. Okuda, and M. Kubo, “Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes,” Journal of Ethnopharmacology, vol. 45, no. 2, pp. 131–139, 1995.
- S. Das and D. K. Das, “Anti-inflammatory responses of resveratrol,” Inflammation and Allergy—Drug Targets, vol. 6, no. 3, pp. 168–173, 2007.
- E. Ignatowicz and W. Baer-Dubowska, “Resveratrol, a natural chemopreventive agent against degenerative diseases,” Polish Journal of Pharmacology, vol. 53, no. 6, pp. 557–569, 2001.
- S. V. Penumathsa, M. Thirunavukkarasu, S. Koneru et al., “Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat,” Journal of Molecular and Cellular Cardiology, vol. 42, no. 3, pp. 508–516, 2007.
- K. K. R. Rocha, G. A. Souza, G. X. Ebaid, F. R. F. Seiva, A. C. Cataneo, and E. L. B. Novelli, “Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets,” Food and Chemical Toxicology, vol. 47, no. 6, pp. 1362–1367, 2009.
- D. Miura, Y. Miura, and K. Yagasaki, “Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats,” Life Sciences, vol. 73, no. 11, pp. 1393–1400, 2003.
- L. Rivera, R. Morón, A. Zarzuelo, and M. Galisteo, “Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats,” Biochemical Pharmacology, vol. 77, no. 6, pp. 1053–1063, 2009.
- J. Ahn, I. Cho, S. Kim, D. Kwon, and T. Ha, “Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet,” Journal of Hepatology, vol. 49, no. 6, pp. 1019–1028, 2008.
- I. J. Cho, J. Y. Ahn, S. Kim, M. S. Choi, and T. Y. Ha, “Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters,” Biochemical and Biophysical Research Communications, vol. 367, no. 1, pp. 190–194, 2008.
- G. M. Do, E. Y. Kwon, H. J. Kim et al., “Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice,” Biochemical and Biophysical Research Communications, vol. 374, no. 1, pp. 55–59, 2008.
- G. V. Gnoni and G. Paglialonga, “Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes,” European Journal of Clinical Investigation, vol. 39, no. 3, pp. 211–218, 2009.
- D. M. Goldberg, S. E. Hahn, and J. G. Parkes, “Beyond alcohol: beverage consumption and cardiovascular mortality,” Clinica Chimica Acta, vol. 237, no. 1-2, pp. 155–187, 1995.
- P. J. Barter, M. Caulfield, M. Eriksson et al., “Effects of torcetrapib in patients at high risk for coronary events,” New England Journal of Medicine, vol. 357, no. 21, pp. 2109–2122, 2007.
- M. Gomaraschi, D. Baldassarre, M. Amato et al., “Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-IMilano mutant,” Circulation, vol. 116, no. 19, pp. 2165–2172, 2007.
- B. L. Trigatti, M. Krieger, and A. Rigotti, “Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 10, pp. 1732–1738, 2003.
- T. B. César, M. R. M. Oliveira, C. H. Mesquita, and R. C. Maranhão, “High cholesterol intake modifies chylomicron metabolism in normolipidemic young men,” Journal of Nutrition, vol. 136, no. 4, pp. 971–976, 2006.
- R. Clarke, C. Frost, R. Collins, P. Appleby, and R. Peto, “Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies,” British Medical Journal, vol. 314, no. 7074, pp. 112–117, 1997.
- M. You and C. Q. Rogers, “Adiponectin: a key adipokine in alcoholic fatty liver,” Experimental Biology and Medicine, vol. 234, no. 8, pp. 850–859, 2009.
- T. Kusakabe, H. Tanioka, K. Ebihara et al., “Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet,” Diabetologia, vol. 52, no. 4, pp. 675–683, 2009.
- C. L. Lin, H. C. Huang, and J. K. Lin, “Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells,” Journal of Lipid Research, vol. 48, no. 11, pp. 2334–2343, 2007.
- J.-F. Liu, Y. Ma, Y. Wang, Z.-Y. Du, J.-K. Shen, and H.-L. Peng, “Reduction of lipid accumulation in HepG2 Cells by luteolin is associated with activation of AMPK and Mitigation of oxidative stress,” Phytotherapy Research, vol. 25, no. 4, pp. 588–596, 2011.
- M. Zang, A. Zuccollo, X. Hou et al., “AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells,” Journal of Biological Chemistry, vol. 279, no. 46, pp. 47898–47905, 2004.
- G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001.
- J. Shang, L. L. Chen, and F. X. Xiao, “Resveratrol improves high-fat induced nonalcoholic fatty liver in rats,” Zhonghua Gan Zang Bing Za Zhi, vol. 16, no. 8, pp. 616–619, 2008.
- J. M. Ajmo, X. Liang, C. Q. Rogers, B. Pennock, and M. You, “Resveratrol alleviates alcoholic fatty liver in mice,” American Journal of Physiology, vol. 295, no. 4, pp. G833–G842, 2008.
- J. Shang, L. L. Chen, F. X. Xiao, H. Sun, H. C. Ding, and H. Xiao, “Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase,” Acta Pharmacologica Sinica, vol. 29, no. 6, pp. 698–706, 2008.
- J. L. Goldstein and M. S. Brown, “Atherosclerosis: the low-density lipoprotein receptor hypothesis,” Metabolism, vol. 26, no. 11, pp. 1257–1275, 1977.
- M. S. Brown and J. L. Goldstein, “Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth,” Journal of Lipid Research, vol. 21, no. 5, pp. 505–517, 1980.
- H. Rudney and R. C. Sexton, “Regulation of cholesterol biosynthesis,” Annual Review of Nutrition, vol. 6, pp. 245–272, 1986.